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Abstract
Background and objectives Population-based data on urinary calcium excretion are scarce. The association of
serum calcium and circulating levels of vitamin D [25(OH)D2 or D3] with urinary calcium excretion in men and
women from a population-based study was explored.
Design, settings, participants, & measurements Multivariable linear regression was used to explore factors
associated with square root–transformed 24-hour urinary calcium excretion (milligrams per 24 hours) taken as
the dependent variable with a focus on month-speciﬁc vitamin D tertiles and serum calcium in the Swiss Survey
on Salt Study.
Results In total, 624 men and 669 women were studied with mean ages of 49.2 and 47.0 years, respectively (age
range=15–95 years). Mean urinary calcium excretion was higher in men than in women (183.05 versus 144.60
mg/24 h; P,0.001). In adjusted models, the association (95% conﬁdence interval) of square root urinary calcium
excretion with protein–corrected serum calcium was 1.78 (95% conﬁdence interval, 1.21 to 2.34) mg/24 h per
milligram per deciliter in women and 0.59 (95% conﬁdence interval, 20.11 to 1.29) mg/24 h per milligram per
deciliter in men. Men in the third 25(OH)D3 tertile had higher square root urinary calcium excretion than men in
the ﬁrst tertile (0.99; 95% conﬁdence interval, 0.36 to 1.63 mg/24 h per nanogram per milliliter), and the corre-
sponding association was 0.32 (95% conﬁdence interval, 20.22 to 0.85) mg/24 h per nanogram per milliliter in
women. These sex differences were more marked under conditions of high urinary sodium or urea excretions.
Conclusions There was a positive association of serum calciumwith urinary calcium excretion in women but not
men. Vitamin 25(OH)D3 was associated with urinary calcium excretion in men but not women. These results
suggest important sex differences in the hormonal and dietary control of urinary calcium excretion.
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Introduction
Calcium ions play a key role in several physiologic
processes in humans, and variations of plasma levels
of calcium (hypo- or hypercalcemia) may have devas-
tating consequences. Tight control of plasma calcium is
achieved by complex regulatory mechanisms, including
calcium-sensing receptor, and calcitropic hormones,
such as vitamin D (1) and parathyroid hormone (PTH)
(2, 3). Two distinct sources of vitamin D are known:
vitamin D2 is mainly provided by food, and vitamin
D3 is synthesized de novo in the skin (4) and constitutes
the major and more potent isoform (5, 6). Both vitamins
D2 and D3 need to be hydroxylated to best ﬁt in the
docking pocket of the vitamin D receptor and trans-
activate target genes. Active 1,25(OH)2 vitamin D is
produced from circulating levels of 25(OH)D (4) by
the activity of the 1a-hydroxylase CYP27B1 and fur-
ther degraded by the activity of CYP24A1 (7). Active
1,25(OH)2D stimulates intestinal calcium absorp-
tion and bone resorption and decreases renal calcium
excretion.
Urinary calcium results from glomerular ﬁltration
of albumin-free plasma calcium and intense calcium
reabsorption along the different tubular segments,
where regulation by several anticalciuretic factors,
such as 1,25(OH)2D, PTH, sex hormones, or dietary
factors, is exerted. Increased urinary calcium excretion—
hypercalciuria—may, thus, derive from excessive intes-
tinal absorption or increased bone resorption, providing
an excessive load to be ﬁltered by the glomerulus, or
may be caused by tubular dysfunction and decreased
reabsorption.
Hypercalciuria was extensively studied in relation
to kidney stone formation (8) and osteoporosis (9, 10).
However, population-based data on urinary calcium
excretion are scarce, and the relationship between serum
calcium and urinary calcium excretion or between circu-
lating 25(OH)D levels and urinary calcium excretion has
surprisingly not been fully explored or remains contro-
versial. Indeed, the InChianti Study found a positive as-
sociation between urinary calcium excretion and
circulating 25(OH) vitamin D in men but not in women.
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In other studies, urinary calcium excretion was positively as-
sociated with 1,25(OH)2 vitamin D3 in middle-aged men with
or without kidney stones. By contrast, Eisner et al. (11) found
no association between urinary calcium excretion and serum
25(OH) vitamin D. Overall, only few data describe sex-speciﬁc
associations of urinary calcium excretion with serum calcium
or vitamin D.
We investigated the association of 24-hour urinary calcium
excretion with circulating vitamin D [25(OH)D2 and/or
25(OH)D3; 25(OH)D3 having a higher level than 25(OH)D2]
and serum calcium by sex in a Swiss population-based sample.
Materials and Methods
Source Population
Methods have been described previously (12). Brieﬂy, data
were used from the Swiss Survey on Salt Intake (SSS) Study
(13) conducted between January of 2010 and March of 2012.
The main goal of the study was to assess the mean dietary
sodium intake.
The SSS Study is a population-based multicenter study
including 1550 people living in the French-, German-, and
Italian-speaking parts of Switzerland. Inclusion criteria were
that participants had to be above 15 years old, permanent
resident of Switzerland, not living in an institution, and able
to answer questions in French, Italian, or German. Partic-
ipants were sampled using eight age (15–29, 30–44, 45–49
and .60 years) and sex strata. Participation rate was 10%.
Participants were informed and gave written consent; the
parents or legal representatives of participants ,18 years
old also gave written consent. The SSS Study fulﬁlled the
tenets of the Declaration of Helsinki and was accepted by
the local institutional ethics committees.
Data Collection
Participants answered a questionnaire on sociodemographic
variables, alcohol consumption, smoking, and kidney stone
status. Resting BP was taken in the sitting position ﬁve times
at both of two visits with an automatic Omron HEM-907
oscillometric device; a nonfasting blood test was taken, and
24-hour urine was collected (unrestricted diets). Of 1550
participants, 1373 participants had 25(OH) vitamin D levels
available, and 80 participants had one or several missing
covariates. Blood and urine were analyzed centrally.
Urine and total serum calcium were measured by the
O-cresolphtalein method. Intra- and interbatch coefﬁcients
of variation (CVs) for urinary values were 0.80% and
1.40% for concentrations of 14.60 and 18.41 mg/dl, respec-
tively; 1.20% and 1.60% for concentrations of 6.23 and 6.15
mg/dl, respectively; and 0.90% and 1.40% for concentra-
tions of 11.03 and 10.91 mg/dl, respectively. Intra- and inter-
batch CVs for serum values were 0.90% and 1.60%,
respectively. Total serum proteins were measured by the
Biuret reaction (intra- and interbatch CVs were 0.60% and
1.00%, respectively); protein-corrected serum calcium was
then calculated (14). Serum 25(OH)D [including vitamin
25(OH)D2 and 25(OH)D3] concentration was measured by
liquid chromatography–tandem mass spectrometry (intra-
and interbatch CVs were 4% and 8%, respectively) (12,15).
Serum urea was measured by the Urease-glutamate deshy-
drogenase method (intra- and interbatch CVs were 0.80%
and 3.40%, respectively). Serum creatinine and urine
creatinine were measured by the Jaffé kinetic compensated
method (intra- and interbatch CVs of serum values were
0.70% and 2.30%, respectively; intra- and interbatch CVs of
urinary values were 2.10% and 2.20% for concentrations of
0.12 and 0.12 mg/dl, respectively; 1.30% and 1.70% for con-
centrations of 0.21 and 0.20 mg/dl, respectively; and 1.10%
and 1.20% for concentrations of 0.60 and 0.58 mg/dl, respec-
tively). Urinary phosphate was determined by the phospho-
molybdate method (intra- and interbatch CVs were 0.70% and
1.30% for concentrations of 86.80 and 83.70 mg/dl, respec-
tively, and 0.80% and 1.40% for concentrations of 43.40 and
43.40 mg/dl, respectively). eGFR was calculated with the
CKD Epidemiology Collaboration equation (16).
Hypercalciuria was deﬁned as urinary calcium excretion
.4 mg/kg per 24 hours (17,18), a deﬁnition used in prior
studies in adults and children. For all other analyses, uri-
nary calcium excretion was not corrected for body weight,
because we wanted to explore the association with body
mass index (BMI; weight per height2 in kilograms per me-
ter2), and most prior studies did not correct for body
weight.
Statistical Analyses
We used Stata 12 (StataCorp LP, College Station, TX) for
statistical analyses. Continuous variables were presented
as means695% conﬁdence intervals, and binary variables
were presented as numbers of participants and percent-
ages. Differences in means and proportions across groups
were tested (and P values were reported) using t and Pear-
son chi-squared tests. To satisfy regression assumptions,
24-hour urinary calcium excretion and 24-hour urinary
phosphate excretion were square root transformed. Serum
25(OH)D [which included vitamin 25(OH)D2 and 25(OH)
D3] was divided into month-speciﬁc tertiles, with the ﬁrst
tertile having the lowest value and the third tertile having
the highest value as previously described (12). Dividing
vitamin D levels into month-speciﬁc tertiles represents
the best way to take into account the seasonal variation
in vitamin D (19). In the ﬁrst stage, vitamin D levels are
divided into tertiles (separate for each month). In the sec-
ond stage, the tertiles are combined across 12 months,
thereby creating month-speciﬁc tertiles.
Multivariable linear regression was used to determine
the association between covariates of interest and 24-hour
urinary calcium excretion as the dependent variable. We
tested a priori–selected interaction with sex. We conducted
separate analyses by sex, because we found signiﬁcant sex
interactions in the ﬁnal model, namely serum calcium by
sex (P,0.01) and 25(OH)D2+3 by sex (P=0.03). Covariates
included age, BMI, mean arterial BP, protein-corrected se-
rum calcium, month-speciﬁc tertiles of vitamin D, eGFR,
24-hour urinary phosphate excretion in grams per 24
hours, 24-hour urinary creatinine excretion in milligrams
per kilogram per 24 hours, 24-hour urinary volume in li-
ters, alcohol use, smoking, physical activity, menopause,
linguistic region, and some drugs related to calcium excre-
tion. Urinary volume and creatinine excretion were included
as covariates to take the completeness of urine collection into
account. Menopause was divided into pre- and postmeno-
pausal status, and smoking status was divided into current
smoker and nonsmoker. Alcohol use was deﬁned as present
if participants reported consuming at least one unit of
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alcohol (including beer, wine, and/or spirits) during the past
7 days. Physical activity was deﬁned as present if partici-
pants reported to have physical activity at least one time per
month. Drugs inﬂuencing calcium homeostasis were added
as covariates, namely calcium supplementation, vitamin D
supplementation, diuretics (which included participants tak-
ing thiazides diuretics [n=8] and loop diuretics [n=1]), corti-
coids, bisphosphonate, angiotensin-converting enzyme
inhibitor (ACEI), angiotensin II receptor blocker (ARB),
and thyroid hormone substitution. Contraceptive pills
were added into the models for premenopausal women,
and hormone replacement therapy was added into the mod-
els for postmenopausal women. We present results for un-
adjusted (model 1) and fully adjusted (model 2) models. The
fully adjusted model included as covariate variables
having a P value ,0.10 in either men and/or women while
forcing linguistic region, ARB, ACEI, diuretics, and vitamin
D supplementation into the model. We used a cutoff of 0.05
for statistical signiﬁcance for main covariates and a cutoff of
0.10 for interaction terms. Analyses were restricted to partic-
ipants with all variables of interests. We conducted sensitiv-
ity analyses to explore whether urinary sodium/potassium/
urea excretion and caffeine intake had a signiﬁcant effect on
the observed associations and also, whether excluding par-
ticipants with self-reported kidney stone status (with no sig-
niﬁcant stone by serum calcium [P.0.60] or 25(OH)D2+3
[P.0.60] interactions in both sexes), those with potential in-
complete urine collection (deﬁned as urine volume below
500 ml or urinary creatinine excretion below sex-speciﬁc per-
centile 5 [13.64 mg/kg per 24 hours in men and 9.28 mg/kg
per 24 hours in women]), those with hypercalcemia (deﬁned
as protein-corrected serum calcium above the 99th percen-
tile: .10.41 mg/dl for men and .10.62 mg/dl for women),
those with eGFR,60 ml/min per 1.73 m2, those taking cal-
cium and/or vitamin D supplements, or those taking anti-
hypertensive treatment inﬂuenced the results. We also
explored whether vitamin D modiﬁed the association of uri-
nary calcium excretion with urinary phosphate excretion (by
including a multiplicative interaction term in the model) or if
it confounded this association. To explore a potential effect
modiﬁcation by dietary factors, we conducted stratiﬁed
analyses by high versus low urinary sodium, potassium, and
urea excretions as well as reported alcohol intake.
Results
We included in this analysis 1293 participants with no
missing values for all variables of interest (83% of the overall
sample). The distributions of 24-hour urinary calcium excre-
tion in this population-based sample were rightly skewed in
both men and women (Figure 1A). After adjusting for
weight, the distribution became similar in men and women
(Figure 1B).
Protein-corrected serum calcium was similar in men and
women (Table 1). Mean (SD) serum vitamin D [25(OH)D2+3]
values in month-speciﬁc tertiles were 14.84 (65.70), 22.86
(64.92), and 33.52 (68.34) in men and 14.87 (65.32), 23.71
(65.14), and 34.93 (67.83) in women for tertiles 1–3, respec-
tively. Men had signiﬁcantly higher 24-hour urinary calcium
excretion than women but not when adjusted for body
weight. This observed sex difference, therefore, merely
reﬂects a difference in body weight. Levels of 25(OH)D3
were much higher than levels of 25(OH)D2 independent of
sex. The distributions of 25(OH)D2 and 25(OH)D3 are shown
in Supplemental Figure 1.
Inwomen, but not inmen, serum calciumwas signiﬁcantly
associated with urinary calcium excretion in multivariable
models (Table 2, Supplemental Table 1). In men, but not in
women, urinary calcium excretion was associated with
month-speciﬁc 25(OH)D2+3 tertiles. These associations were
independent of urinary sodium excretion, urinary potassium
excretion, urinary urea excretion, caffeine intake (not shown
here), kidney stone status, urine collection, eGFR,60 ml/min
per 1.73 m2, hypercalcemia (.10.41 mg/dl for men and.10.62
mg/dl for women), vitamin D and calcium supplementa-
tion, and antihypertensive treatment. ACEIs were negatively
associated with urinary calcium excretion in men and
women. ARBs were strongly negatively associated with uri-
nary calcium in women, with weaker negative associations
in men. In our data, vitamin D did not modify the associa-
tion of urinary calcium excretion with urinary phosphate
excretion (no effect modiﬁcation and no confounding ef-
fect). Seasonal variations in urinary calcium excretion
were minor and only occurred in men, with a signiﬁcantly
lower excretion in winter compared with summer (not shown
here).
When differentiating 25(OH)D2 and 25(OH)D3, urinary
calcium excretion remained associated with serum calcium
in women but not in men (Table 3, Supplemental Table 2).
In men, urinary calcium excretion was associated with 25
(OH)D3 month-speciﬁc tertiles but not 25(OH)D2. In
women, urinary calcium excretion was not associated
Figure 1. | Distribution of 24-hour urinary calcium excretion in. (A)
Milligrams per 24 hours and (B) milligrams per kilogram per 24 hours
by sex. Distribution is illustrated by Kernel density.
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with month-speciﬁc 25(OH)D tertiles, regardless of the vi-
tamin D subtype.
Figure 2 illustrates the sex differences in the adjusted as-
sociation of urinary calcium excretion with protein-corrected
serum calcium and 25(OH)D2+3.
Stratiﬁed analyses by low versus high urinary sodium,
potassium, and urea excretions and alcohol intake can be found
in Supplemental Table 3. These dietary factors did not signif-
icantly modify the associations of interest in men. By contrast,
the associations of urinary calcium excretion with serum cal-
cium and vitamin D tertiles differed between high versus low
urinary sodium excretion strata in women. Furthermore, the
sex-by–serum calcium and sex-by–vitamin D interactions (for
their effects on urinary calcium excretion) were more signiﬁ-
cant under conditions of high urinary sodium excretion and
high urinary urea excretion (Supplemental Table 4).
We found no signiﬁcant association of hypercalciuria
with age, BMI categories, or vitamin D tertiles (Figure 3). In
women, hypercalciuria prevalence was positively associated
with tertiles of serum calcium (4.7%–11.4%; P=0.02). The
prevalence values of hypercalciuria were 9.0% and 8.1% in
men and women, respectively; 8.4% and 7.4% in nonstone-
forming men and women, respectively; and 14.3% and
16.7% in stone-forming men and women, respectively.
Discussion
In this cross-sectional population-based study, 24-hour
urinary calcium excretion was strongly and positively asso-
ciatedwith serum calcium inwomen but not men. By contrast,
24-hour urinary calcium excretion was associated positively
with month-speciﬁc vitamin D tertiles in men but not women.
Table 1. Participants’ characteristics by sex
Participants’ Characteristics Men (n=624) Women (n=669) P Value
Urinary calcium excretion (mg/24 h) 183.05 (6104.18) 144.60 (683.14) ,0.001
Urinary calcium excretion (mg/kg per 24 h) 2.27 (61.25) 2.23 (61.25) 0.53
Age (yr) 49.2 (618.1) 47.0 (617.9) 0.02
French-speaking region 199 (31.8%) 218 (32.5%)
German-speaking region 339 (54.3%) 358 (53.5%)
Italian-speaking region 86 (13.7%) 93 (13.9%) 0.95
Menopause — 295 (44.1%) NA
Alcohol user 535 (85.7%) 443 (66.2%) ,0.001
Smoking 110 (17.1%) 107 (15.9%) 0.43
Physical activity .1 time/mo 314 (50.3%) 324 (48.3%) 0.49
Self-reported kidney stone 63 (10.1%) 48 (7.2%) 0.06
Body mass index (kg/m2) 26.1 (64.2) 24.4 (64.6) ,0.001
Mean arterial BP (mmHg) 94.0 (610.6) 87.7 (610.4) ,0.001
Protein-corrected serum calcium (mg/dl) 9.22 (60.38) 9.23 (60.40) 0.57
eGFR (ml/min per 1.73 m2) 89.7 (619.0) 90.2 (619.5) 0.58
Serum urea (mg/dl) 36.23 (612.69) 30.32 (68.69) ,0.001
25(OH)D2+3 month-speciﬁc (ng/ml) 0.03
Tertile 1 14.84 (65.70) 14.87 (65.32)
Tertile 2 22.86 (64.92) 23.71 (65.14)
Tertile 3 33.52 (68.34) 34.93 (67.83)
25(OH)D2 month-speciﬁc (ng/ml) 0.24
Tertile 1 0.42 (60.13) 0.44 (60.13)
Tertile 2 0.72 (60.12) 0.72 (60.12)
Tertile 3 1.25 (60.53) 1.25 (60.62)
25(OH)D3 month-speciﬁc (ng/ml) 0.07
Tertile 1 14.06 (65.64) 14.31 (65.47)
Tertile 2 22.10 (65.04) 23.09 (65.06)
Tertile 3 32.71 (68.46) 34.46 (67.75)
Urinary creatinine excretion (mg/kg per 24 h) 21.54 (64.88) 16.91 (64.53) ,0.001
24-h Urinary volume (L) 1.7 (1.2–2.3) 1.9 (1.2–2.5) 0.05
Urinary phosphate excretion (g/24 h) 1.00 (60.17) 0.82 (60.15) ,0.001
Angiotensin-converting enzyme inhibitor 38 (6.0%) 23 (3.4%) 0.02
Angiotensin receptor blocker 65 (10.4%) 41 (6.1%) ,0.01
Calcium supplementation 6 (0.9%) 39 (5.8%) ,0.001
Vitamin D supplementation 6 (0.9%) 12 (1.7%) 0.20
Corticoid 1 (0.1%) 0 0.48
Thyroid hormone 4 (0.6%) 28 (4.1%) ,0.001
Diuretics 5 (0.8%) 4 (0.6%) 0.66
Oral contraception — 85 (12.7%) NA
Hormonal substitution — 46 (6.8%) NA
Data are means (6SDs), medians (interquartile ranges), and n (percentages) unless otherwise speciﬁed. eGFR was calculated by the
CKD Epidemiology Collaboration equation. NA, not available.
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The association of urinary calcium excretion with vitamin D
was mainly explained by 25(OH)D3 and not 25(OH)D2. These
results suggest important sex differences in the relationships
of urinary calcium excretion with serum calcium and vitamin
D levels in the population.
Serum calcium was associated positively with urinary
calcium excretion in women independent of menopausal
status and hormonal supplementation. No such clear-cut
positive association was observed in men. Our results contrast
with those of prior smaller-sized studies. In the InChianti
Study (n=595) (10), an association between serum calcium
and 24-hour urinary calcium excretion was observed in
men but not women. Peacock et al. (20) found a positive as-
sociation between serum calcium load and urinary calcium
excretion in 72 men and women. Both studies differ from our
study in many ways, including differences in sample size,
recruitment, inclusion criteria, and covariates considered,
which may explain these discrepancies. A possible explana-
tion for the observed sex differences could be the role of sex
hormones. In animal studies, estrogen was found to stimulate
calcium reabsorption in the kidney (21), whereas testosterone
was found to inhibit it (22). Alternatively, CYP24A1 or
CYP27B1 activity might differ in men and women (23). Estro-
gens seem to suppress CYP24A1 transcripts and therefore,
induce the accumulation of 1,25(OH)2D3. Another explana-
tion for the observed sex differences is diet. In women only,
we found that urinary calcium excretion was more strongly
associated with serum calcium under conditions of high com-
pared with low salt intake. Interestingly, the association of
urinary calcium excretion with serum calcium was similar in
men and women under conditions of low urinary sodium
excretion and low urea excretion, which suggests that dietary
salt and protein intakes may explain, as least partly, the ob-
served sex differences.
In this study, men in the highest month-speciﬁc 25(OH)
D2+3 tertile excreted a higher level of urinary calcium com-
pared with men in the lowest tertile, whereas no such asso-
ciation was found in women. These results are similar for
25(OH)D3 alone but not for 25(OH)D2. The lack of associa-
tion between 25(OH)D2 and urinary calcium excretion could
be explained by the very low circulating level of vitamin D2
compared with D3 in this study.
Our ﬁndings are in line with those of the InChianti Study,
which included patients over 65 years old (10). Results on the
relationship between vitamin D (and its different forms) and
urinary calcium excretion are inconsistent in studies includ-
ing selected groups of participants. A positive association
with 1,25(OH)2D in men and women with urolithiasis (D2
and D3 were not differentiated) (24) and 25(OH)D3 (25) have
been described. Another study found a positive association
with 1,25(OH)2D3; it included middle-aged men and com-
pared 109 stone formers with 109 controls (26). In a clinical
trial including six men on different calcium diets, urinary
calcium excretion was positively associated with 25(OH)D
(D2 and D3 were not differentiated) (27). Volunteers (men
and women included) (28) showed a slight increase in uri-
nary calcium excretion after vitamin D3 supplementation or
exposure to ultraviolet B light. A weak correlation (r=0.27)
was found in a study including 160 renal stone formers and
217 nonstone formers (29) between 25(OH)D (D2 and D3
were not differentiated) and urinary calcium excretion. In
contrast, no association was found in a study including
169 stone formers (11) [25(OH)D was used as the dependent
variable, and D2 and D3 were not differentiated]. A possible
explanation for the sex difference that we observed is sex
hormones. A previous clinical trial showed that estrogens
have a stimulatory effect on 1a-hydroxylase, increasing the
synthesis of 1,25(OH)2D3 and vitamin D–binding protein but
not 25(OH)D3 (30). Another explanation for the observed sex
difference is diet, which was discussed for serum calcium.
Both ACEIs and ARBs were negatively associated with
urinary calcium excretion independent of other factors.
Whereas these associations were similar in men and women
for ACEIs, they were stronger in women than men for ARBs.
Figure 2. | Relationship of 24-hour urinary calcium excretion with
protein-corrected serum calcium and serum 25(OH)D2+3 by sex. (A)
Relationship of square root–transformed adjusted urinary calcium
excretion (milligrams per 24 hours) with protein-corrected serum
calcium. (B) Relationship of square root–transformed adjusted urinary
calcium excretion (milligrams per 24 hours) with vitamin 25(OH)D2+3.
(C) Relationship of square root–transformed adjusted urinary calcium
excretion (milligrams per kilogram per 24 hours adjusted for weight)
with protein-corrected serum calcium. (D) Relationship of square root–
transformed adjusted urinary calcium excretion (milligrams per kilo-
gram per 24 hours adjusted for weight) with vitamin 25(OH)D2+3. We
used separate models for men and women. Models were adjusted for
age, body mass index, mean arterial BP, eGFR, 24-hour urinary phos-
phate excretion, 24-hour urinary creatinine excretion, 24-hour urinary
volume, alcohol use, smoking status, linguistic region, and some drugs
related to calcium excretion: angiotensin receptor blockers, angiotensin-
converting enzyme inhibitors, calcium and vitamin D supplementa-
tion, diuretics, (BandD)protein-corrected serumcalcium, and (AandC)
25(OH)D2+3. The graphs show linear fits and 95% confidence intervals
for adjusted residuals.
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Although the mechanism underlying the observed associa-
tions is unknown, angiotensin type I receptors are present on
bone cells, and in vitro studies suggest that angiotensin I and
II could stimulate bone resorption (31). Also, ACEIs have been
associated with reduced fracture risk (32) and reduced calciuria
(33,34). By contrast, ACEI, but not ARB, use was associated
with a small increase in bone loss restricted to the hip during
follow-up in older men (35). Despite some level of inconsis-
tency across studies, currently available evidence suggests that
ACEIs and ARBs reduce urinary calcium excretion.
We found a hypercalciuria prevalence of 8.1% in women
and 9.0% in men on unrestricted diets using as a cutoff of
4.0 mg/kg per 24 hours. This is lower than was found in
prior studies (36). However, these studies were not popula-
tion based, were of much smaller size, and used a different
deﬁnition for hypercalciuria. In the literature, hypercalciuria
was also deﬁned as .200 mg/24 h (37) in adults on a diet
restricted in calcium, phosphorus, and sodium (including
men and women nonstone formers, hypercalciuric stone
formers, and normocalciuric stone formers). In nonstone-
forming women from two different cohorts, the prevalence
values of hypercalciuria were 27% (n=99; mean age of 61
years old) and 17% (n=30; mean age of 42 years old) (36).
Additionally, in nonstone-forming men, the prevalence
was 14% (n=110; mean age of 60 years old). In this study,
hypercalciuria was deﬁned as .250 mg/24 h in women
and .300 mg/24 h in men on unrestricted diets (36).
The fact that urinary phosphate excretion is higher in men
in our study is probably because of higher nutritional intake.
Dietary phosphate is known to strongly inﬂuence urinary
phosphate excretion (38), and men are known to have higher
dietary phosphate intake than women (39).
Figure 3. | Prevalence of hypercalciuria (>4mg/kg per 24 hours) by sex (men are shown as black bars, and women are shown as white bars).
Hypercalciuria prevalence by sex across (A) age strata, (B) body mass index (BMI) strata, (C) tertiles of protein-corrected calcium, (D) month-
specific tertiles of vitamin D2+3, (E) month-specific tertiles of vitamin D2, and (F) month-specific tertiles of vitamin D3.
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The strengths of this multicentric study are its population-
based nature covering the three main linguistic regions of
Switzerland, the availability of urinary electrolyte excre-
tion measured in 24-hour urine, and the centralized labora-
tory measurements. Serum vitamin D was measured using
the gold standard method (liquid chromatography-tandem
mass spectrometry), and we used month-speciﬁc vitamin D
tertiles, which are known to reduce seasonal bias. There are
some limitations, such as the low participation rate, which
limits external validity, and the fact that calcium and vitamin
D supplementations used were not speciﬁcally detailed from
participants, although medication information was taken.
Although we cannot exclude that some supplementations
have not been reported, this is unlikely to have a strong
effect on the results, and this would mainly affect vitamin
D2. The active form of vitamin D, 1,25(OH)2D, was not
tested. We do not have detailed information on outdoor
activities and clothing habits, and therefore, we cannot
evaluate the role of exposure to sunlight on the explored
associations. Serum phosphate was only available for a
subset of participants, and PTH and bone minerals pa-
rameters were not available. The absence of a signiﬁcant
association of urinary calcium excretion with menopausal
status in the fully adjusted model was unexpected. How-
ever, urinary calcium excretion was associated positively
with menopausal status when serum calcium, calcium,
and vitamin D supplements were not included as covari-
ates in the model.
In conclusion, we found important sex differences in the
association of 24-hour urinary calcium excretion with serum
calcium and serum 25(OH)D2 and/or serum 25(OH)D3 in
this population-based study. Additional studies are needed
to understand the mechanisms underlying these sex differ-
ences and particularly, the inﬂuence of sex hormones and/or
dietary factors on urinary calcium excretion.
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